Potential benefits of precise corticosteroids therapy for severe 2019-nCoV pneumonia

Signal Transduction and Targeted Therapy

Volumn 5, Issue 1, 2020, Pages

  Zhou, Wei ^a   Liu, Yisi ^b   Tian, Dongdong ^c   Wang, Cheng ^d   Wang, Sa ^e   Cheng, Jing ^f   Hu, Ming ^g   Fang, Minghao ^f   Gao, Yue ^a  

^a BEIJING INSTITUTE OF RADIATION MEDICINE   (China)

^b CAPITAL MEDICAL UNIVERSITY   (China)

^c HEBEI GENERAL HOSPITAL   (China)

^d CHINESE PLA GENERAL HOSPITAL   (China)

^e THE SECOND AFFILIATED HOSPITAL OF ZHEJIANG UNIVERSITY SCHOOL OF MEDICINE   (China)

^f HUAZHONG UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

^g Wuhan Pulmonary Hospital   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; HYDROCORTISONE; METHYLPREDNISOLONE; ANTIVIRUS AGENT;

ADULT RESPIRATORY DISTRESS SYNDROME; ARTIFICIAL VENTILATION; AVASCULAR NECROSIS; COMMUNITY ACQUIRED PNEUMONIA; CORONAVIRUS DISEASE 2019; CORTICOSTEROID THERAPY; CRITICALLY ILL PATIENT; FOLLOW UP; HUMAN; HYPERGLYCEMIA; INFLUENZA A (H1N1); LETTER; LUNG FIBROSIS; LUNG INJURY; MORTALITY; MULTIPLE ORGAN FAILURE; OXYGEN SATURATION; PSYCHOSIS; RESPIRATORY DISTRESS; RISK FACTOR; SALVAGE THERAPY; SEPTIC SHOCK; SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2; VIRUS PNEUMONIA; BETACORONAVIRUS; CHINA; COMPLICATION; CORONAVIRUS INFECTION; CRITICAL ILLNESS; DOSE CALCULATION; EPIDEMIOLOGY; PANDEMIC; PATHOGENICITY; PATHOLOGY; PRACTICE GUIDELINE;

ADRENAL CORTEX HORMONES; ANTIVIRAL AGENTS; BETACORONAVIRUS; CHINA; CORONAVIRUS INFECTIONS; CRITICAL ILLNESS; DRUG DOSAGE CALCULATIONS; HUMANS; METHYLPREDNISOLONE; PANDEMICS; PNEUMONIA, VIRAL; PRACTICE GUIDELINES AS TOPIC; RESPIRATION, ARTIFICIAL; RESPIRATORY DISTRESS SYNDROME, ADULT; SALVAGE THERAPY; SHOCK, SEPTIC;

EID: 85081997738     PISSN: 20959907     EISSN: 20593635     Source Type: Journal    
DOI: 10.1038/s41392-020-0127-9     Document Type: Letter

References (12)

1. National Health Commission of the People’s Republic of China. National Health Commission’s briefing on the pneumonia epidemic situation released on 10 Feb 2020 (in Chinese). http://www.nhc.gov.cn/xcs/yqtb/202002/167a0e01b2d24274b03b2ca961107929.shtml (2020).
2. Wang, W., Tang, J. & Wei, F. Updated understanding of the outbreak of 2019 novel coronavirus (2019-nCoV) in Wuhan, China. J. Med. Virol. 10.1002/jmv.25689 (2020).
3. National Health Commission of the People’s Republic of China. The 5th trial version of Diagnosis and Treatment Scheme for Pneumonitis with 2019-nCoV Infection (In Chinese). http://www.nhc.gov.cn/yzygj/s7653p/202002/d4b895337e19445f8d728fcaf1e3e13a.shtml (2020).
4. Russell, C. D., Millar, J. E. & Baillie, J. K. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury. Lancet. 10.1016/s0140-6736(20)30317-2 (2020).
5. Jiang, S. et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: a meta-analysis. Medicine 98, e16239 (2019).
6. Arabi, Y. M. et al. Corticosteroid therapy for critically ill patients with Middle East Respiratory Syndrome. Am. J. Respir. Crit. Care Med. 197, 757–767 (2018).
7. Stockman, L. J., Bellamy, R. & Garner, P. SARS: systematic review of treatment effects. PLoS Med. 3, e343 (2006).
8. Moreno, G. et al. Corticosteroid treatment in critically ill patients with severe influenza pneumonia: a propensity score matching study. Intensive Care Med. 44, 1470–1482 (2018).
9. Marik, P. E. Steroids for sepsis: yes, no or maybe. J. Thorac. Dis. 10, S1070 (2018).
10. Rhodes, A. et al. Surviving sepsis campaign: international guidelines for management of sepsis and septic shock: 2016. Crit. Care Med. 45, 486–552 (2017).
11. Biffl, W. L. et al. Are corticosteroids salvage therapy for refractory acute respiratory distress syndrome? Am. J. Surg. 170, 591–595 (1995). discussion 595−596.
12. Li, H. et al. Effect of low-to-moderate-dose corticosteroids on mortality of hospitalized adolescents and adults with influenza A(H1N1)pdm09 viral pneumonia. Influenza Other Respir. Viruses 11, 345–354 (2017).